Trustmark National Bank Trust Department’s BioMarin Pharmaceuticals BMRN Stock Holding History

Trustmark National Bank Trust Department’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-6	Closed	-$1K	–	272
2019 Q2	$1K	Hold	6	–	–	﹤0.01%	518
2019 Q1	$1K	Hold	6	–	–	﹤0.01%	527
2018 Q4	$1K	Hold	6	–	–	﹤0.01%	519
2018 Q3	$1K	Buy	+6	New	+$599	﹤0.01%	534

Other funds holding BMRN

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Trustmark National Bank Trust Department's BMRN Position: Q3 2019 in Review

Trustmark National Bank Trust Department sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2019, closing a stake of 6 shares — an estimated $1K sold.

Trustmark National Bank Trust Department first reported a position in BMRN in Q3 2018 and held it in 4 quarters. The position peaked at $1K in Q2 2019. 437 funds tracked by Wall St. Rank hold BMRN as of Q3 2019.

Trustmark National Bank Trust Department reported no remaining BioMarin Pharmaceuticals position as of Q3 2019 after selling out during the quarter.
Trustmark National Bank Trust Department sold 6 BioMarin Pharmaceuticals shares in Q3 2019, an estimated $1K.
Trustmark National Bank Trust Department first reported a position in BioMarin Pharmaceuticals in Q3 2018 and held it in 4 quarters.
Trustmark National Bank Trust Department's BioMarin Pharmaceuticals position peaked at $1K in Q2 2019.
437 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2019.

Based on Trustmark National Bank Trust Department's 13F filing for Q3 2019, filed 14 Nov 2019.